Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013 - Volume 21, Number 1—January 2015 - Emerging Infectious Disease journal - CDC
Volume 21, Number 1—January 2015
Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013
For >100 years, countries in the meningitis belt of Africa have experienced intermittent epidemics of meningococcal meningitis, caused mainly by the serogroup A meningococcus (1). After development and prequalification of a new serogroup A meningococcal polysaccharide/tetanus toxoid conjugate vaccine (PsA-TT) in 2009 (2), vaccination with PsA-TT across the meningitis belt commenced in 2010, starting with persons 1–29 years of age in Burkina Faso and parts of Mali and Niger (3). Little transmission of the serogroup A meningococcus was occurring in these countries at the time of vaccine introduction, making evaluation of its effectiveness difficult.
In contrast, in Chad, PsA-TT was introduced in the middle of a serogroup A meningococcal epidemic, and vaccination with PsA-TT commenced at the end of 2011, shortly before the 2012 epidemic season. At this time, vaccination of persons 1–29 years of age (target 1.8 million) was undertaken in the capital N’Djamena, Mayo Kebbi Est, and Chari Baguirmi (4), designated here as the N’Djamena regions (Figure 1). In 2012, the vaccination program was extended to the rest of the country (target 5.9 million) (Figure 1). During the 2012 meningitis season, the incidence of meningitis decreased by >90% in vaccinated areas compared with the rest of the country, and a similar reduction in the incidence of carriage of serogroup A Neisseria meningitidis was found, as reported previously (4). We report on the incidence of meningitis during the 2013 meningitis season after vaccination of persons 1–29 years of age in areas with no prior vaccination program.
Dr. Gamougam is head microbiologist at the reference laboratory of the Hôpital Générale de Référence Nationale, N’Djaména, Chad. Her research interest is bacterial meningitis.
We acknowledge the major contributions of the Meningitis Vaccine Project and their colleagues in the control of epidemic meningitis in Africa through the development of PsA-TT.
This study was supported by the MenAfriCar consortium with funding from the Bill and Melinda Gates Foundation and the Wellcome Trust.
- Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg. 1999;93:341–53 .PubMed
- Frasch CE, Preziosi MP, LaForce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac TM. Hum Vaccin Immunother.2012;8:715–24.PubMed
- Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine. 2012;30(Suppl 2):B40–5 .PubMed
- Daugla DM, Gami J, Gamougam K, Naibei N, Mbainadji L, Narbe M, Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. Lancet. 2014;383:40–7.PubMed
- Caugant DA, Kristiansen PA, Wang X, Mayer LW, Taha MK, Ouedraogo R, Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS ONE. 2012;7:e46019 .PubMed
- Novak RT, Kambou JL, Diomande FV, Tarbangdo TF, Ouedraogo-Traore R, Sangare L, Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis. 2012;12:757–64 .PubMed
- Kristiansen PA, Diomande F, Ba AK, Sanou I, Ouedraogo AS, Ouedraogo R, Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2013;56:354–63 .PubMed
- Broome CV, Rugh MA, Yada AA, Giat L, Giat H, Zeltner JH, Epidemic group C meningococcal meningitis in Upper Volta, 1979. Bull World Health Organ. 1983;61:325–30 .PubMed
- Decosas J, Koama JB. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis.2002;2:763–5.PubMed
- Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, Maïnassara HB, Meningococcal meningitis: unprecedented incidence of serogroup X–related cases in 2006 in Niger. Clin Infect Dis. 2007;44:657–63 .PubMed
- Dakar Discussion Group on Priorities for Research on Epidemic Meningococcal Disease in Africa. Altmann D, Aseffa A, Bash M, Basta N, Borrow R, Broome C, et al. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine. 2013;31:1453–7.
Suggested citation for this article: Gamougam K, Daugla DM, Toralta J, Ngadoua C, Fermon F, Page AL, et al. Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013. Emerg Infect Dis [Internet]. 2015 Jan [date cited]. http://dx.doi.org/10.3201/eid2101.140256
No hay comentarios:
Publicar un comentario